A non-invasive cardiac mapping system transforming arrhythmia diagnosis and treatment through real-time 3D insights

The challenge

In 2023, circulatory diseases were the leading cause of death in the EU, accounting for 1.7 million deaths (32.7% of total)1 Among these, cardiac arrhythmias—affecting an estimated 240 to 400 million people globally—represent a significant health burden due to their potential to cause stroke and sudden death2, 3.

The most common sustained cardiac arrhythmia is atrial fibrillation (AF), characterized by an irregular and often rapid heart rhythm. As of 2019, AF affected approximately 59.7 million people worldwide, with numbers expected to rise due to aging populations and improved detection. In the EU alone, over 11 million people live with AF, and this number is projected to double by 20604.

AF poses serious risks to patients, significantly increasing the likelihood of stroke, heart failure, and premature death. It also causes debilitating symptoms such as palpitations, fatigue, and shortness of breath, which severely impact quality of life and mental health. Unfortunately, treatments often fall short—up to 50% of patients experience recurrence after the first ablation, particularly in persistent AF cases, requiring multiple procedures and increasing emotional and physical burden. The financial impact is substantial, both in terms of out-of-pocket expenses and indirect costs like lost income due to hospitalizations and ongoing symptoms. In Europe, AF-related healthcare costs represent 1–3% of total national health expenditures, with estimated annual costs reaching €13.5 billion5, 6.

 

Healthcare professionals face their own challenges: the lack of precise, non-invasive cardiac mapping tools makes it difficult to accurately localize arrhythmogenic sites. Current invasive techniques are time-consuming and limited in scope, complicating treatment planning. This contributes to clinician frustration, rising workloads, and burnout as AF prevalence continues to grow.

For healthcare systems and policymakers, AF represents a growing public health concern. With an aging population and rising prevalence, the burden on national budgets is significant—Germany alone spends over €3 billion annually on AF-related care. While there’s strong pressure to adopt innovative medical technologies that improve patient outcomes and reduce costs, updating reimbursement frameworks remains a complex and slow-moving process.

Recognizing these unmet needs, the Strategic Research Agenda for Cardiovascular Disease (SRA-CVD) by the European Research Area Network on Cardiovascular Diseases (ERA-CVD) has identified improvement in arrhythmia treatment as a priority. Central to this is the ability to accurately localize the arrhythmogenic site within the myocardium. The success of ablation interventions, a key treatment strategy, depends on precisely identifying the pathological region of the heart muscle.

However, a major limitation in current mapping systems is their inability to provide full-volume visualization of cardiac electrical activity with high temporal and spatial resolution. Endocardial mapping can only assess the inner heart surface and fails to detect arrhythmias originating from the epicardium or mid-myocardium. These blind spots contribute significantly to the high failure rates of cardiac ablations and highlight the urgent need for technological innovation in cardiac mapping.

The solution

Corify Care’s ACORYS technology is a cutting-edge, non-invasive cardiac mapping system developed to precisely identify arrhythmogenic sites in patients with atrial fibrillation (AF) and other complex arrhythmias.

As a Digital Medical Device, ACORYS integrates advanced software algorithms with specialized hardware to produce real-time, three-dimensional maps of the heart’s electrical activity—providing insights far beyond those offered by traditional invasive techniques. It supports a range of medical applications, including diagnosis, monitoring, and treatment guidance for cardiac arrhythmias.

ACORYS stands out for its speed and accuracy: it can generate cardiac maps up to 10 times faster than conventional methods, reducing mapping time from 30 minutes to just 3. This efficiency enables rapid, data-driven clinical decisions and has demonstrated a significant improvement in ablation success rates—from 48% to 89% 7.

Corify’s innovation journey has been strongly supported by EIT Health. In 2019, the AF-FINE project helped refine both the ACORYS technology and Corify’s business model, culminating in the 2020 Award for Europe’s Most Innovative Product from the EIT. Continued support came through the Amplifier SAVE-COR project, which was instrumental in obtaining the CE Mark for ACORYS.

ACORYS has since undergone extensive clinical validation, having been used in more than 1,400 patients across several hospitals in Spain, with pilot programs also conducted in Portugal and Sweden.

Expected impact

Health Impacts will be tracked through clinical studies, measuring a 48% to 86% increase in arrhythmia treatment efficacy. ACORYS will also enable real-time global mapping, accelerating the process from 30 minutes with standard catheter mapping to just 3 minutes. Expected results include reductions in both 23 complications and re-interventions, as well as optimized therapeutic planning, all aimed at advancing cardiovascular research and improving patient outcomes.

Economic Impacts include reductions in procedure times and inpatient stays, allowing more efficient use of medical staff and optimized operating room scheduling, thus lowering costs associated with resource use in specialized care areas.

Environmental Impacts include reduced wear on invasive, high-tech equipment, and a decrease in consumables, such as catheters, which will be measured by comparing usage levels before and after ACORYS’s implementation.

Expected social outcomes include improved clinical outcomes with reduced long-term disability and dependence, faster outpatient procedures that lower travel and lodging costs, quicker patient return to work, and a reduced burden on caregivers.

External Partners
  • Corify Care SL (Activity Leader)
  • Charité – Universitätsmedizin Berlin
  • University Hospital Frankfurt / Goethe University Frankfurt
References

[1] Eurostat 2023 https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Cardiovascular_diseases_statistics

[2] Li, et al. (2022). “Global, regional, and national burden of disease study of atrial fibrillation/flutter, 1990–2019: results from a global burden of disease study, 2019.“ BMC Public Health, https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-022-14403-2

[3] Van Gelder, et al. (2024). “2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)“, European Heart Journal, https://doi.org/10.1093/eurheartj/ehae176

[4] Hidrincks et al., (2021). “ 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC“, European Heart Journal, 10.1093/eurheartj/ehaa612

[5] Camm et al., (2012). “2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association”, European Heart Journal, 10.1093/eurheartj/ehs253

[6] Fuster et al., (2006). “2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines”, European Heart Journal, 10.1093/eurheartj/ehl176

[7] Invers et al., (2024). “ Regional conduction velocities determined by noninvasive mapping are associated with arrhythmia-free survival after atrial fibrillation ablation“, Heart Rhythm, 10.1016/j.hrthm.2024.04.063

Andreu Climent
| CEO | Corify Care
Contact
Almudena Albertos
| Project manager | Corify Care
Contact